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Abstract: A major obstacle for preclinical testing of Alzheimer’s disease (AD) therapies is the availabil-
ity of translationally relevant AD models. Critical for the validation of such models is the application
of the same approaches and techniques used for the neuropathological characterization of AD. Deposi-
tion of amyloid-￿ 42 (A￿42) plaques and neurofibrillary tangles containing phospho-Tau (pTau) are the
pathognomonic features of AD. In the neuropathologic evaluation of AD, immunohistochemistry (IHC)
is the current standard method for detection of A￿42 and pTau. Although IHC is indispensable for de-
termining the distribution of AD pathology, it is of rather limited use for assessment of the quantity
of AD pathology. We have recently developed Luminex-based assays for the quantitative assessment
of A￿42 and pTau in AD brains. These assays are based on the same antibodies that are used for the
IHC-based diagnosis of AD neuropathologic change. Here we report the application and extension of
such quantitative AD neuropathology assays to commonly used genetically engineered AD models and to
animals that develop AD neuropathologic change as they age naturally. We believe that identifying AD
models that have A￿42 or pTau levels comparable to those observed in AD will greatly improve the ability
to develop AD therapies. Abbreviations: Alzheimer’s disease (AD); amyloid ￿ 42 (A￿42); phospho-Tau
(pTau); immunohistochemistry (IHC).
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